Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,221.53 -1.15 (-0.02%) Dow
39,465.40 -47.44 (-0.12%) Nasdaq
16,380.15 +39.28 (+0.24%) Bitcoin USD
62,675.32 +1,218.22 (+1.98%) CMC Crypto 200
1,290.37 +30.17 (+2.39%)
Oncotelic Therapeutics, Inc. (OTLC)
- GlobeNewswire
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024
AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager, will be presenting: Nanomedicines: Past, Present, Future. For additional information please go to: https://nexus-conference.com/ddnwest/. Dr. Hu is an experienced Biomaterial Scientist with expertise in nanomedicine, biologics, vaccines, cell, in vivo, gene therapy, drug development processes. He has gre
- GlobeNewswire
Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
AGOURA HILLS, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that it has entered into a binding term-sheet with Mosaic ImmunoEngineering, Inc. (OTCPK: CPMV) (“Mosaic”) under which Mosaic will acquire rights to Oncotelic’s clinical-stage necroptosis cancer therapies. Oncotelic’s necroptosis therapeutics work by disrupting tumor blood flow resulting in immunogenic tumor cell death through “death re
- GlobeNewswire
Linkage of Cancer and Lupus in Gliomas Patients
AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas: Past, Present, and Future Strategies in the Treatment and Management of Gliomas. Dr. Vuo
